eligibility_summary
Eligibility: Adults 18–75 with progressive MM after 1–3 prior lines (incl lenalidomide), measurable disease (PI may allow non‑measurable), prior anti‑CD38/carfilzomib allowed if ≥PR, no progression ≤60 d, no AE stop, ECOG 0–2, CrCl ≥60, adequate marrow/liver, anticoagulation‑tolerant, contraception. Exclude: refractory anti‑CD38, PCL/POEMS/amyloidosis, COPD FEV1<50%, pregnancy, uncontrolled HTN/DM/infection, active HBV/HCV(no SVR)/HIV, major CV disease, QTc>470, LVEF<40%, severe neuropathy, prior iberdomide.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in relapsed/refractory multiple myeloma tests Iber-KDd (iberdomide + daratumumab + carfilzomib + dexamethasone) for 8 cycles, then iberdomide maintenance. Iberdomide: oral CELMoD (cereblon E3 ligase modulator) promoting IKZF1/3 (Ikaros/Aiolos) degradation, directly cytotoxic to myeloma and enhances T/NK-cell activation and cytokine production. Daratumumab: anti-CD38 monoclonal antibody mediating CDC, ADCC, ADCP, apoptosis, and depleting CD38+ immunosuppressive cells. Carfilzomib: IV epoxyketone proteasome inhibitor irreversibly inhibiting 20S β5 (chymotrypsin-like) activity, causing proteotoxic/ER stress and apoptosis. Dexamethasone: glucocorticoid with lympholytic, anti-myeloma, anti-inflammatory effects. Targets/pathways: malignant plasma cells, CD38, CRBN–Ikaros/Aiolos axis, ubiquitin–proteasome system, T/NK effector function. Premeds mitigate daratumumab reactions.